AMPX vs XMTR

AMPX exhibits weak deterministic health with a Piotroski F-Score of 1/9, indicating severe financial distress and poor operational efficiency, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite this, the stock is trading at a premium valuation (Forward P/E: 182.91, Price/Sales: 33.78) driven by extraordinary revenue growth (137.4% YoY) and strong earnings surprises (average +52.81% over last 4 quarters). Analyst consensus is strongly bullish with a 'strong_buy' rating and a $20.00 target, reflecting high growth expectations. Insider selling activity (8 transactions, $37.78M) introduces bearish sentiment, but the company's technical trend and recent price momentum suggest strong market confidence. The Graham Number and intrinsic value are unavailable, indicating no defensive margin of safety.

XMTR presents a classic growth-stage profile with a critical divergence between operational momentum and financial health. The Piotroski F-Score of 2/9 indicates significant fundamental weakness, yet the company has successfully pivoted toward profitability with a 166.7% YoY EPS growth and consistent earnings beats. While revenue growth remains strong at 29.5%, the bearish insider sentiment and high Price-to-Book ratio suggest the current valuation may be ahead of the underlying financial stability.